undefined undefined undefined

Imaging or biomarkers: which is superior in risk prediction?

Event: ESC Congress 2023

Topic: Cardiovascular Risk Assessment

Session type: Abstract Sessions

Access

Like

How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options

Event: ESC Congress 2022

Topic: Cardiovascular Pharmacotherapy

Session type: Symposium

Access

Like

Prevention of cardiovascular diseases in the post-COVID19 era

Event: ESC Congress 2022

Topic: Prevention

Session type: Satellite Symposium

Access

Like

Cardiac biomarkers for atherosclerotic cardiovascular disease risk prediction

Event: ESC Congress 2021 - The Digital Experience

Topic: Biomarkers

Session type: Advances in Science

Access

Like

Emerging role of cardiac biomarkers in cardiovascular risk stratification

Event: ESC Preventive Cardiology 2021

Topic: Biomarkers

Session type: Satellite Symposium

Access

Like

Non-troponin biomarkers in acute coronary syndromes

Event: ESC Congress 2019

Topic: Biomarkers

Session type: Abstract Sessions

Access

Like

Emerging evidence-based approaches to reduce residual atherosclerotic risk

Event: ESC Congress 2018

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Access

Like

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)

Event: ESC Congress 2017

Topic: Drug therapy

Session type: Satellite Symposium

Access

Like

PCSK9i: translating LDL-C lowering into plaque regression and CV event reduction?

Event: ESC Congress 2016

Topic: Atherosclerosis

Session type: Satellite Symposium - Experts on the Spot

Access

Like

The relevance of biomarkers: a never ending story

Event: ESC Congress 2016

Topic: Biomarkers

Session type: Moderated Posters

Access

Like

undefined undefined undefined

Contributor content

Imaging or biomarkers: which is superior in risk prediction?

How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options

Prevention of cardiovascular diseases in the post-COVID19 era

Cardiac biomarkers for atherosclerotic cardiovascular disease risk prediction

Emerging role of cardiac biomarkers in cardiovascular risk stratification

Non-troponin biomarkers in acute coronary syndromes

Emerging evidence-based approaches to reduce residual atherosclerotic risk

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)

PCSK9i: translating LDL-C lowering into plaque regression and CV event reduction?

The relevance of biomarkers: a never ending story

ESC 365 is supported by